Pressemitteilung BoxID: 863938 (trans-o-flex Express GmbH)
  • trans-o-flex Express GmbH
  • Hertzstraße 10
  • 69469 Weinheim
  • Ansprechpartner
  • Sabine Kolaric

Investment in state-of-the-art transport fleet technology: 165 new delivery vehicles for ThermoMed

Three different types of vehicles for different tour distances: VW Transporter, Mercedes-Benz Vito and Sprinter

(PresseBox) (Weinheim, ) trans-o-flex ThermoMed, the specialist for the actively temperature-controlled transportation of pharmaceuticals within the range of 2 to 8 °C, is going to replace a large part of its transport fleet. The company has ordered a total of 165 new delivery vehicles, all of which will be delivered by the end of this year. The first vehicles have already been in operation since the middle of June. “With the purchase of the new vehicles, we take another step towards increasing our reliability, efficiency and eco-friendliness”, says Wolfgang P. Albeck, CEO of trans-o-flex.

In order to reach these goals, trans-o-flex ThermoMed decided to purchase three different types of vehicles, which will be deployed depending on the tours’ requirement profiles. The order includes 46 VW T6 Transporters and 46 Mercedes-Benz Vito vans as well as 73 Mercedes Sprinters with box bodies. All of the vehicles have been awarded a pharma certificate and meet the Euro 6 standard. They consume less diesel than their predecessors and their engines are cleaner. Nitric oxide (NOx) emissions, for instance, are more than 50 % lower (from 0.18 to 0.08 g/km). In addition to this, the vehicles have also been awarded an ATP certificate (for the FRCX category). Thus, with respect to the insulation of the loading space and the performance of the temperature control unit, the vehicles meet the highest international standards for refrigerated vehicles.

“This new investment of several millions of euros is part of the continuous modernisation and expansion of our entire transport fleet“, explains Albeck. Just a few weeks ago, at the beginning of June, trans-o-flex announced to purchase 81 new pharma-certified refrigerated trailers.

Website Promotion

trans-o-flex Express GmbH

The trans-o-flex Group's core competence focuses on the provision of logistic solutions for the pharmaceutical, cosmetics and consumer electronics industries as well on the transportation of other high-quality, sensitive goods. For the transportation of pharmaceutical products, trans-o-flex has built a nationwide network that includes active temperature control and full documentation. To this end, the company, in its Pharma Logistics business area, has installed transport systems that are suitable for the transportation of pharmaceutical products in the temperature ranges of between 15 and 25 °C and between 2 and 8 °C in compliance with the EU directives for the transportation of pharmaceutical products. In its Technology Logistics business area, trans-o-flex organises transports for customers from other industries, mainly consumer electronics. These customers also benefit from the high standards with respect to safety, hygiene, reliability and transparency which trans-o-flex has established for the pharmaceutical industry. In its Contract Logistics business area, trans-o-flex bundles services from storage and picking & packing up to individual value-added services. At an international level, trans-o-flex focuses on the implementation of logistic concepts via the networks EUROTEMP (temperature-controlled logistics) and EURODIS (in 36 European countries). Both nationally and internationally, trans-o-flex, in contrast to 100-% parcel services, delivers both goods in parcels and on pallets and also offers special services, such as the transportation of hazardous goods (without being limited to small quantities), express and time-window deliveries as well as direct deliveries. Thus, the company covers the entire logistic chain from procurement and warehousing to distribution and fulfilment. In 2016, annual sales of the trans-o-flex Group, which has a workforce of approximately 1,900 employees, amounted to ca. € 490 million. For more information, go to